Glucarpidase

(Voraxaze®)

Voraxaze®

Drug updated on 4/15/2024

Dosage FormInjection (intravenous; 1,000 units/vial)
Drug ClassCarboxypeptidases
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Glucarpidase (Voraxaze) is indicated for the treatment of toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. It provides a targeted approach to rapidly reducing methotrexate levels, presenting itself as a potentially safer and more effective alternative to extracorporeal treatments.
  • The utility of glucarpidase compared to extracorporeal treatments in managing severe methotrexate toxicity was evaluated in a systematic review/meta-analysis.
  • Compared with other management strategies such as intravenous hydration and folinic acid, glucarpidase is recommended over extracorporeal methods, which mainly remove drugs from the intravascular compartment without significantly addressing drugs that distribute into cells like methotrexate does.
  • A study cited within the systematic review suggests lower mortality rates among patients treated with glucarpidase than those treated with hemodialysis. However, limitations were noted regarding study design and evidence quality.
  • Despite these limitations, there is an overall recommendation against using extracorporeal treatments when glucarpidase is available, based on its potential effectiveness and safety profile, especially for patients suffering from high-dose methotrexate toxicity coupled with impaired renal function.
  • The data reviewed included 109 patients receiving varying doses of Methotrexate (>0.5 g/m² or ≤0.5 g/m²), indicating consideration across different levels of exposure; reported mortality rates were 19.5% for high-dose users versus 26.7% for low-dose users, highlighting severity conditions addressed by this drug treatment option.